Moleculin Biotech (MBRX) Reports FY22, Provides Pipeline Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Moleculin Reports Full Year 2022 Financial Results and Provides Pipeline Update
March 23, 2023 7:10 AM EDT2022 marked by continued execution and growing body of positive data across clinical and preclinical development programs
Sufficient capital to fund operations into the third quarter of 2024
Company to host conference call and webcast today at 8:30 AM ET
HOUSTON, March 23, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX)... More
